Difference between revisions of "NK- and T-cell lymphoma - historical"
Jump to navigation
Jump to search
(Created page with "The purpose of this page is to provide references to regimens that are obsolete, outdated, or of historical interest only. As a general rule, this includes the inferior arm(s)...") |
m |
||
| Line 8: | Line 8: | ||
=Relapsed or refractory= | =Relapsed or refractory= | ||
==Pembrolizumab monotherapy {{#subobject:84ac5y|Regimen=1}}== | ==Pembrolizumab monotherapy {{#subobject:84ac5y|Regimen=1}}== | ||
| − | <div class="toccolours" style="background-color:# | + | <div class="toccolours" style="background-color:#ee6b6e"> |
===Regimen {{#subobject:ga3na4|Variant=1}}=== | ===Regimen {{#subobject:ga3na4|Variant=1}}=== | ||
{| class="wikitable" style="width: 40%; text-align:center;" | {| class="wikitable" style="width: 40%; text-align:center;" | ||
Revision as of 17:30, 3 November 2023
The purpose of this page is to provide references to regimens that are obsolete, outdated, or of historical interest only. As a general rule, this includes the inferior arm(s) of a randomized study, unless said regimens continue to be recommended by trustworthy sources such as the NCCN Guidelines. Is there a regimen missing from this list? See the main NKTCL page for current regimens.
1 regimens on this page
1 variants on this page
|
Relapsed or refractory
Pembrolizumab monotherapy
References
- Kwong YL, Chan TSY, Tan D, Kim SJ, Poon LM, Mow B, Khong PL, Loong F, Au-Yeung R, Iqbal J, Phipps C, Tse E. PD1 blockade with pembrolizumab is highly effective in relapsed or refractory NK/T-cell lymphoma failing l-asparaginase. Blood. 2017 Apr 27;129(17):2437-2442. Epub 2017 Feb 10. link to original article PubMed